dimnp

Logo CALYM HD Uze
  

 

 

Uzé Team

A member of the CALYM Carnot Institute

 

Team

BORDAT Yann

AI CNRS

yan.bordat arobase univ-montp2.fr

CARTRON Guillaume

PCH CHU

guillaume.cartron arobase univ-montp2.fr

DE CEUNINCK Leentje Post-doc leentje.deceuninck arobase umontpellier.fr

GARCIN Genevieve

Post-doc VIB

genevieve.garcin arobase univ-montp2.fr 

OGOR Thomas Doctorant thomas.ogor arobase umontpellier.fr
UZE Gilles DR CNRS gilles.uze arobase univ-montp2.fr

 

 

- 2015 Publications -

Zhang, X., Bogunovic, D., Payelle-Brogard, B., Francois-Newton, V., Speer, S., Yuan, C., Volpi., S., Li, Z., Sanal, O., Mansouri, D., Tezcan, I., Rice, G.I., Chen, C., Mansouri, N., Mahdaviani, S-A., Itan, Y., Boisson, B., Okada, S., Zeng, L., Wang, X., Jiang, H., Liu, W., Han, T., Liu, D., Ma., T., Wang, B., Liu, M., Liu, J., Wang, Q.K., Yalnizoglu, D., Radoshevich, L., Uzé, G., Gros, P., Rozenberg, F., Zhang, S-Y., Jouanguy, E., Bustamante, J., García-Sastre, A., Abel, L., Lebon, P., Notarangelo, L.D., Boisson-Dupuis, S., Crow, Y.J., Casanova, J-L. and Pellegrini, S.(2015) Human intracellular ISG15 prevents IFN-α/β over-amplification and auto-inflammation. Nature. 517. 89-93.

Sultanik P-S., Casrouge  A., Alanio C., Mottez E., Rosa-Hézode I., Hézode C., Renard P., Bousquet L., Pelle  P., Uzé G., Pol S., Albert M.L. and Mallet V. J. (2015) Baseline sensitivity of T cells to alpha-interferon correlates with sustained virological response to IFN-based triple therapy in HCV infection. Viral Hepatitis.  22(6):524-34. doi: 10.1111/jvh.12355. Epub 2014 Nov 10.
Uzé G. and Tavernier, J. (2015) High efficiency targeting of IFN-α activity: possible applications in fighting tumors and infections. Cytokine and Growth Factor Reviews. 26(2):179-82. doi: 10.1016/j.cytogfr.2014.10.006

Wilmes S., Beutel O., Li Z., Franҫois-Newton V., Richter C.P., Janning D., Kroll C., Hanhart P., Hötte K., You C., Uzé G., Pellegrini S.and Piehler J. (2015) Receptor dimerization dynamics as regulatory valve for plasticity of type I interferon signalling. J. Cell Biol. 209: 579-593.


Paul F., Pellegrini S. and Uzé G. IFNA2: The prototypic human alpha interferon. (2015) Gene. 567: 132-137.

Livingstone M., Sikström K., Robert P.A., Uzé G., Larson O. and Pellegrini S. Assessment of mTOR-dependent translational regulation of interferon stimulated genes. (2015) PLos One. 10(7): e0133482.

 

- 2014 Publications -

Garcin G., Paul F., Staufenbiel, M., Bordat Y., Van der Heyden, J., Wilmes, S., Cartron G.,4, Apparailly, F., De Koker, S., Piehler, J., Tavernier, J. and Uzé G. (2014) High efficiency cell−specific targeting of cytokine activity. Nature Commun. 5:3016 doi: 10.1038/ncomms4016.

Sistigu  A., Yamazaki T., Vacchelli E., Chaba K., Enot D.P., Adam J., Vitale I., Goubar A., Baracco E.E., Remédios C., Fend L., Hannani D., Aymeric L., Ma Y., Niso-Santano M., Kepp O., Schultze J.L., Tüting T., Belardelli F., Bracci L., La Sorsa V., Ziccheddu G., Sestili P., Urbani F., Delorenzi M., Lacroix-Triki  M., Quidville V., Conforti R., Spano J-P., Pusztai L., Poirier-Colame V., Delaloge, S., Penault-Llorca F., Ladoire S., Arnould L., Cyrta J., Marie-Charlotte Dessoliers M-C., Eggermont A., Bianchi M.E., Pittet M., Engblom C., Pfirschke C., Préville X., Uzé G., Schreiber R.D., Chow M.T., Smyth M.J., Proietti  E., André F., Kroemer G. and Zitvogel L. (2014) Cancer cell-autonomous contribution of Type 1 interferon signaling to the efficacy of chemotherapy. Nature Medecine. 11. 1301-1309.

Tomasello E., Pollet E., Vu-Manh T-P., Uzé G. and Dalod M. (2014) Harnessing mechanistic knowledge on beneficial versus deleterious IFN-I effects to design innovative immunotherapies targeting cytokine activity to specific cell types. Frontiers in Immunology. 5. 526.

Comet N.R., Aguiló J.I., Rathoré M.G., Catalán E., Garaude J., Uzé G., Naval J., Pardo J., Villalba M., and Anel A. (2014) IFN-α signaling through PKC-θ is essential for anti-tumoral NK cell function Oncoimmunology. 3. e948705.

Cartron G., de Guibert S., Dilhuydy MS., Morschhauser F., Leblond V., Dupuis J., Mahe B., Bouabdallah R., Lei G., Wenger M., Wassner-Fritsch E.; Hallek M. (2014) Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study.Blood. 124(14):2196-202. doi: 10.1182/blood-2014-07-586610. Epub 2014 Aug 20.

Gagez AL., Cartron G. (2014) Obinutuzumab: a new class of anti-CD20 monoclonal antibody.Curr Opin Oncol. 26(5):484-91. doi: 10.1097/CCO.0000000000000107.

Gagez AL., Cartron G. (2014) Obinutuzumab: a new class of anti-CD20 monoclonal antibody.Curr Opin Oncol. 26(5):484-91. doi: 10.1097/CCO.0000000000000107.

 

- 2013 Publications -

Uzé G., (2013) Interféron et immunité anticancéreuse. In Thérapie ciblée des cancers. Les cibles de l'immunité. Vol 8, JohnLibbey Eurotext Ed. pp 34−43.


Bachy E., Houot R., Morschhauser F., Sonet A., Brice P., Belhadj K., Cartron G., Audhuy B., Ferme C., Feugier P., Sebban C., Delwail V., Maisonneuve H., Le Gouill S., Lefort S., Brousse N., Foussard C., and Salles G.  (2013) Long-term follow-up of the FL2000 studycomparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma.Haematologica.  98(7):1107-14. doi: 10.3324/haematol.2012.082412. Epub 2013 May 3.


Garcin G., Bordat Y., Chuchan P., Monneron D., Law H.K.W., Piehler J. and Uzé G.  (2013) Differential activity of type I interferon subtypes for dendritic cell differentiation. PloS One. (20138(3) : e58465 (IF 4.09)


Morschhauser F., Cartron G., Solal-Céligny P., Haioun C., Bouabdallah R., Feugier P., Bouabdallah K., Asikanius E., Lei G., Wenger M., Wassner-Fritsch E., Salles GA. (2013) Obinutuzumab (GA101) Monotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma or Mantle Cell Lymphoma: Results From the Phase II GAUGUIN Study.J Clin Oncol. In Press. (IF 18.37)


Salles GA., Morschhauser F., Solal-Céligny P., Thieblemont C., Lamy T., Tilly H., Gyan E., Lei G., Wenger M., Wassner-Fritsch E., and Cartron G. (2013) Obinutuzumab (GA101) in Patients With Relapsed/Refractory Indolent Non-Hodgkin’s Lymphoma: Results of the Phase II GAUGUIN Study J Clin Oncol. In Press. 31(23):2920-6. doi: 10.1200/JCO.2012.46.9718. Epub 2013 Jul 8.